7-27-04

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR VITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR BOX 1450-ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

Attorney's Docket No.: 00032.04CON

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/816,567

Filed:

4/1/2004

Title

DELIVERY OF COMPOUNDS FOR THE TREATMENT OF

PARKINSONS THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date:

SEP. 24 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/816,567 Application Number **TRANSMITTAL** 4/1/2004 Filing Date **FORM** Joshua D. Rabinowitz First Named Inventor (to be used for all correspondence after initial filing) Art Unit Not yet known **Examiner Name** To be assigned Total Number of Pages in This Submission Attorney Docket Number 00032.04CON **ENCLOSURES** (check all that apply) After Allowance communication Drawing(s) Fee Transmittal Form to Group . Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to Group Petition Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) \_\_ Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Info. Discl. Statemetn (2 pp.) Form 1449 (3 copies, 8 pages each)
Copy of references 169 Incomplete Application Response to Missing Parts Return Postcard under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm

# Firm or Individual name ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Customer Number 37485 Elaine C. Stracker, Ph.D., J.D. Telephone (650)-687-3905 Date SEP. 2 4 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name Elaine C. Stracker

Signature Date SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1 of 8

For PTO-1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00032.04CON Application Number: 10/816,567

Applicant: Joshua D. RABINOWITZ et al.

Filing Date: 4/1/2004 Group Art Unit: Not Yet Known

### U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			
	4.	09/17/1991	5,049,389	Radhakrishnan			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	08/12/1997	5,655,523	Hodson et al.			
	8.	12/09/1997	5,694,919	Rubsamen et al.			
	9.	04/07/1998	5,735,263	Rubsamen et al.			
	10.	04/14/1998	5,738,865	Baichwal et al.			
	11.	04/14/1998	5,738,865	Baichwal et al.			
	12.	06/02/1998	5,758,637	Ivri et al.			
	13.	06/29/1999	5,915,378	Lloyd et al.			
	14.	08/10/1999	5,934,272	Lloyd et al.			-
	15.	09/28/1999	5,957,124	Lloyd et al.			,
	16.	10/05/1999	5,960,792	Lloyd et al.			
	17.	11/30/1999	5,993,805	Sutton et al.			
	18.	03/28/2000	6,041,777	Faithfull et al.			
	19.	04/18/2000	6,051,566	Bianco			
	20.	08/01/2000	6,095,153	Kessler et al.			
······································	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
,	24.	11/06/2001	6,313,176	Ellinwood, Jr. et al.			

**EXAMINER:** 

DATE CONSIDERED:

Choot 2 of 8

		FION DISCLOS N AN APPLICA	URE CITATION TION	Applicant: Joshua D. R.	ABINOWI	IIZ et al.	,
	(Use several sheets if necessary)			Filing Date: 4/1/2004	Group	Art Unit: 1	Not Yet Known
	25.	01/14/2003	6,506,762	Horvath et al.			
	26.	02/04/2003	6,514,482	Bartus et al.			
	27.	07/15/2003	6,591,839	Meyer et al.			
	28.	09/06/2001	US 2001/0020147	Staniforth et al.			
	29.	03/28/2002	US 2002/0037828	Wilson et al.			
	30.	05/16/2002	US 2002/0058009	Bartus et al.			
	31.	07/04/2002	US 2002/0086852	Cantor			
	32.	08/22/2002	US 2002/0112723	Schuster et al.			
	33.	11/28/2002	US 2002/0176841	Barker et al.			
	34.	01/02/2003	US 2003/0004142	Prior et al.			
	35.	02/13/2003	US2003/0032638	Kim et al.			
	36.	08/04/2003		ERY CORPORATION PA			
	37.	08/04/2003	10/633,877 I	Hale et al.			
	37. 38.	08/04/2003 12/30/2003	10/633,877 I 10/749,537 I	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39.	08/04/2003 12/30/2003 12/30/2003	10/633,877 I 10/749,537 I 10/749,539 I	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al.			
	37. 38. 39. 40.	08/04/2003 12/30/2003 12/30/2003 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.			
	37. 38. 39. 40. 41.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II	Hale et al. Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II 10/766,634 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II 10/767,115 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II 10/767,115 II 10/768,205 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II 10/767,115 II 10/768,205 II 10/768,220 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II 10/767,115 II 10/768,205 II 10/768,220 II 10/768,281 II	Hale et al. Hale et al. Rabinowitz et al.			
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48.	08/04/2003 12/30/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004 01/29/2004	10/633,877 II 10/749,537 II 10/749,539 II 10/766,149 II 10/766,279 II 10/766,566 II 10/766,574 II 10/766,634 II 10/766,647 II 10/767,115 II 10/768,205 II 10/768,201 II 10/768,220 II 10/768,281 II 10/768,293 II	Hale et al. Hale et al. Rabinowitz et al.			

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449				Docket Number: 00032.04CON Application Number: 10/816,56		
INF	INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Applicant: Joshua D. RABINOWITZ et al.		
·				Filing Date: 4/1/2004	Group Art Unit: Not Yet Known	
		·	•			
	52.	01/30/2004	10/769,051	Rabinowitz et al.		
	53.	01/29/2004	10/769,157	Rabinowitz et al.		
	54.	01/29/2004	10/769,197	Rabinowitz et al.		
	55.	02/09/2004	10/775,583	Rabinowitz et al.		
	56.	02/09/2004	10/775,586	Rabinowitz et al.		
<del></del>	57.	03/03/2004	10/791,915	Hale et al.		
	58.	03/03/2004	10/792,001	Rabinowitz et al.		
	59.	03/03/2004	10/792,012	Hale et al.		
	60.	03/03/2004	10/792,013	Rabinowitz et al.		
	61.	03/03/2004	10/792,096	Hale et al.	,4	
	62.	03/03/2004	10/792,239	Hale et al.		
<del>.</del>	63.	03/31/2004	10/813,721	Rabinowitz et al.		
	64.	03/31/2004	10/813,722	Rabinowitz et al.		
	65.	03/31/2004	10/814,690	Rabinowitz et al.		
	66.	03/31/2004	10/814,998	Rabinowitz et al.		
	67.	04/01/2004	10/815,527	Rabinowitz et al.		
	68.	04/01/2004	10/816,407	Rabinowitz et al.		
	69.	04/01/2004	10/816,492	Rabinowitz et al.		
	70.	08/04/2004	10/912,462	Hale et al.		
	71.	01/23/2003	US 2003/0015196	Hodges et al.		
	72.	04/03/2003	US 2003/0062042	Wensley et al.		
	73.	11/13/2003	US 2003/0209240	Hale et al.		
	74.	01/02/2003	US 2003/0000518	Rabinowitz et al.		
	75.	01/09/2003	US 2003/0005924	Rabinowitz et al.		
	76.	01/09/2003	US 2003/0005925	Hale et al.		
	77.	01/09/2003	US 2003/0007933	Rabinowitz et al.		
	78.	01/09/2003	US 2003/0007934	Rabinowitz et al.		
	79.	01/16/2003	US 2003/0012737	Rabinowitz et al.		
	80.	01/16/2003	US 2003/0012738	Rabinowitz et al.		
	•					
EXA	AMINER:	•		DATE CONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 4 of 8

Form PTO-1449				Docket Number: 00032.04CON	Application Number: 10/816,567	
INF	INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Applicant: Joshua D. RABINOWITZ et al.		
				Filing Date: 4/1/2004	Group Art Unit: Not Yet Known	
	81.	1/16/2003	US 2003/0012740	Rabinowitz et al.		
	82.	01/23/2003	US 2003/0015189	Rabinowitz et al.		
	83.	01/23/2003	US 2003/0015190	Rabinowitz et al.		
	84.	01/23/2003	US 2003/0017114	Rabinowitz et al.		
	85.	01/23/2003	US 2003/0017115	Rabinowitz et al.		
	86.	01/23/2003	US 2003/0017116	Rabinowitz et al.		
•	87.	01/23/2003	US 2003/0017117	Rabinowitz et al.		
•	88.	01/23/2003	US 2003/0017118	Rabinowitz et al.		
	89.	01/23/2003	US 2003/0017119	Rabinowitz et al.		
	90.	01/23/2003	US 2003/0017120	Rabinowitz et al.		
	91.	1/30/2003	US 2003/0021753	Rabinowitz et al.		
	92.	01/30/2003	US 2003/0021754	Rabinowitz et al.		
	93.	01/30/2003	US 2003/0021755	Hale et al.		
	94.	02/20/2003	US 2003/0035776	Hodges et al.		
	95.	05/15/2003	US 2003/0091511	Rabinowitz et al.		
	96.	05/27/2004	US 2004/010148	Hale et al.		
	97.	07/31/2003	US 2003/0138382	Rabinowitz		
	98.	11/06/2003	US 2003/0206869	Rabinowitz et al.		
	99.	01/15/2004	US 2004/0009128	Rabinowitz et al.		
	100.	05/20/2004	US 2004/0096402	Hodges et al.		
	101.	05/27/2004	US 2004/0099269	Hale et al.		
	102.	06/03/2004	US 2004/0105818	Hale et al.	·	
	103.	06/03/2004	US 2004/0105819	Hale et al.		
	104.	07/01/2004	US 2004/0126326	Rabinowitz et al.		
	105.	07/01/2004	US 2004/0126327	Rabinowitz et al.		
	106.	07/01/2004	US 2004/0126328	Rabinowitz et al.		
	107.	07/01/2004	US 2004/0126329	Rabinowitz et al.		
	108.	07/01/2004	. US 2004/0127481	Rabinowitz et al.		
	109.	07/01/2004	US 2004/0127490	Rabinowitz et al.		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Sheet 5 of 8

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Docket Number: 00032:04CON	Application Number: 10/816,567
				Applicant: Joshua D. RABINOWITZ et al.	
		(Use several sheets if	necessary)	Filing Date: 4/1/2004	Group Art Unit: Not Yet Known
	110.	08/12/2004	US 2004/0156788	Rabinowitz et al.	
	111.	08/12/2004	· US 2004/0156789	Rabinowitz et al.	
	112.	8/12/2004	US 2004/0156790	Rabinowitz et al.	
	113.	08/12/2004	US 2004/0156791	Rabinowitz et al.	

### FOREIGN PATENT DOCUMENTS

- Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	114.	03/14/1990	EP 0 358 114	Europe			
	115.	07/03/2001 .	EP 1 080 720	Europe			
	116.	08/29/2001 .	EP 0 606 486	Europe			
•	117.	02/14/1985	WO 85/00520	WIPO			
	118.	06/13/1991 .	WO 91/07947	WIPO	•		
-	119.	04/11/1996 .	WO 96/09846	WIPO			·
	120.	05/09/1996 .	WO 96/13161	WIPO		,	
	121.	05/09/1996 .	WO 96/13290	WIPO			
	122.	05/09/1996 -	WO 96/13291	WIPO			
	123.	05/09/1996	WO 96/13292	WIPO			
	124.	10/03/1996	WO 96/30068	WIPO			,
	125.	08/07/1997 .	WO 97/27804	WIPO			
	126.	05/28/1998 .	WO 98/22170	WIPO			
	127.	07/23/1998 ,	WO 98/31346	WIPO			
	128.	08/27/1998	WO 98/36651	WIPO			
	129.	04/08/1999 .	WO 99/16419	WIPO			
	130.	12/16/1999	WO 99/64094	WIPO			
	131.	01/06/2000 ,	WO 00/00176	WIPO			
	132.	01/06/2000	WO 00/00215	WIPO			

**EXAMINER:** 

DATE CONSIDERED:

DTO	1 4 4 0			Dock	cet Number: 00032.04CO	N Application No	Sheet 6 o
Form PTO-1449				DOCKET NUMBER: 00032.04CON		1.77	
INFORI	INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant:	Joshua D. R.A	BINOWITZ et	al.
		se several sheets if nece	•	Filing Date:	4/1/2004	Group Art Uni	: Not Yet Known
				<u></u>			
	133.	05/18/2000	WO 00/27363	WIPO			
	134.	05/25/2000	WO 00/29053	WIPO			
	135.	09/17/2000	WO 00/47203	WIPO			
	136.	11/02/2000	WO 00/64940	WIPO			
	137.	11/09/2000 .	WO 00/66084	WIPO			
	138.	11/09/2000	WO-00/66206	WIPO			
	139.	12/21/2000	WO 00/76673	WIPO			
	140.	01/25/2001 -	WO 01/05459	WIPO			
	141.	03/28/2002	WO 02/24158	WIPO	<u>.</u>		
	142.	03/28/2002	WO 02/24158	WIPO			
				= .			
					•		•
						•	
	•		•		•		
				· .		•	:
			•				
•		•					
•	•						

EXAMINER:

DATE CONSIDERED:

Sheet 7 of 8

Form PTO-1449	Docket Number: 00032.04CON	Application Number: 10/816,567
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Joshua D. RAB	INOWITZ et al.
(Use several sheets if necessary)	Filing Date: 4/1/2004	Group Art Unit: Not Yet Known

# OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	143.	Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," <i>Annual Surg.</i> 195(6):700-705.
	144.	Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiological effects," <i>Psychopharmacology</i> (Berl). 102:443-450.
	145.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
	146.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
	147.	Database Biosis "Online!" Biosciences Information Service, Philadelphia, PA 1979, Knight, V. et al., "Amantadine aerosol in humans", database accession no. PREV 198069035552 abstract, &Antimicrobial Agents and Chemotherapy 16(5):572-578.
	148.	Database Biosis "Online!" Biosciences Information Service, Philadelphia, PA 1979, Wilson. S.Z. et al., "Amatadine Aerosol Particle Aerosol Generation and Delivery to Man" Database accession no. PREV198069008137, abstract & Proceedings of the Society for Experimental Biology and Medicine 161(3):350-354.
	149.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiology 32(5):591-600.
	150.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
	151.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
	152.	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
· ·	153.	Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." <i>Pharmacology Biochemistry &amp; Behavior</i> . 36(1):1-7.
	154.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.

EXAMINER:

DATE CONSIDERED:

Form PTO-1449		Docket Number: 00032.04CON	Application Number: 10/816,567		
	ON DISCLOSURE CITATION AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.			
	lse several sheets if necessary)	Filing Date: 4/1/2004	Group Art Unit: Not Yet Known		
	· · · · · · · · · · · · · · · · · · ·	<u> </u>			
155.	Huizer, H., "Analytical studies on illic Pharmaceutisch Weekblad Scientific E		ation during heroin smoking."		
156.	Hurt, R.D., MD and Robertson, C.R., Industry's Secrets About Nicotine: Th	PhD, (October 1998). "Prying Ope Minnesota Tobacco Trial," <i>JAI</i>	pen the Door to the Tobacco MA 280(13):1173-1181.		
157.	Lichtman, A.H. et al. (1996). "Inhalati in Mice," Journal of Pharmacology an	on Exposure to Volatilized Opio d Experimental Therapeutics. 27	ids Produces Antinociception 9(1):69-76.		
158.	Martin, B.R. and Lue, L.P. (May/June Analytical Toxicology 13:158-162.	1989). "Pyrolysis and Volatiliza	tion of Cocaine," Journal of		
159.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.	. "Smoked heroin self-administr	ation in rhesus monkeys,"		
160.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.	th Drugs of Abuse, "NIDA Rese	earch Monograph, (1997)		
161.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," Drug and Alcoh	ogical effects of methamphetamine and other stimulants via whol Dependence. 53:111-120.			
162.	Office Action mailed 8/13/2003 for US BENZODIAZEPINES THROUGH	US application 10/153,313 filed 05/21/2002 "DELIVERY OF SH AN INHALATION ROUTE"			
163.	Pankow, J.F. et al. (1997). "Conversion Free-Base Form Through the Action of				
164.	Pankow, J. (March 2000). ACS Confe pp. 1-8.	rence-San Francisco-3/26/00. Ch	emistry of Tobacco Smoke.		
165.		of Nicotine in Tobacco. Thermal Transfer of Nicotine and e Gas Phase, "J. Agric. Food Chem. 47(12):5133-5145.			
166.	Sekine, H. and Nakahara, Y. (1987). "Inhalation Efficiency and Pyrolysis Pr 32(5):1271-1280.				
167.	Vapotronics, Inc. (1998) located at <a href="https://https://https://https://html.nc.1998">https://html.nc.1998</a> ) located at <a href="https://html.nc.1998">https://html.nc.1998</a> ) located at <a href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998"="" https:="">https://html.nc.1998</a> ) located at <a href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998"="" https:="">https://html.nc.1998</a> ) located at <a href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998"="" https:="">https://html.nc.1998</a> ) located at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a a="" href="https://html.nc.1998&lt;/a&gt;) at &lt;a href=" html.nc.1998<="" https:="">) at <a generation<br="" href="htt&lt;/td&gt;&lt;td&gt;p://www.vapotronics.com.au/bar&lt;/td&gt;&lt;td&gt;nner.htm., 11 pages, (visited on&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;168.&lt;/td&gt;&lt;td&gt;Ward, M.E. MD, et al. (December 199 Administration from a Novel Aerosol 62(6):596-609.&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;169.&lt;/td&gt;&lt;td&gt;Wood, R.W. et al. (1996). ">Pyrolyzate, Methylecgonidine, and De Biochemistry &amp; Behavior. 55(2):237-2</a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a>	monstration of Their Biological			
EXAMINER:		DATE CONSIDERED:			
	ial if citation considered, whether or not the citation considered. Include a copy of this form with r		ine through the citation if not in		

Form PTO-14498

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00032.04CON | Application Number: 10/816,567

Applicant: Joshua D. RABINOWITZ et al.

Filing Date: 4/1/2004 Group Art Unit: Not Yet Known

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If
							Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			
	4.	09/17/1991	5,049,389	Radhakrishnan			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.		-	
	7.	08/12/1997	5,655,523	Hodson et al.			
	8.	12/09/1997	5,694,919	Rubsamen et al.			
	9.	04/07/1998	5,735,263	Rubsamen et al.			
	10.	04/14/1998	5,738,865	Baichwal et al.			
<u> </u>	11.	04/14/1998	5,738,865	Baichwal et al.			
	12.	06/02/1998	5,758,637	Ivri et al.			
	13.	06/29/1999	5,915,378	Lloyd et al.			
	14.	08/10/1999	5,934,272	Lloyd et al.			
	15.	09/28/1999	5,957,124	Lloyd et al.			
	16.	10/05/1999	5,960,792	Lloyd et al.			
	17.	11/30/1999	5,993,805	Sutton et al.			
	18.	03/28/2000	6,041,777	Faithfull et al.			
	19.	04/18/2000	6,051,566	Bianco		·	
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
	24.	11/06/2001	6,313,176	Ellinwood, Jr. et al.			

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE